Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis

Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.

Authors

Stefano Molica¹, Diana Giannarelli², Tycho Baumann³, Emili Montserrat³

Affiliations

¹ Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
² Biostatistic Unit, Regina Elena National Institute for Cancer Treatment and Research, Rome, Italy.
³ Department of Hematology, Hospital Clinic, University of Barcelona, Barcelona, Spain.

PMID: 31957067
DOI: 10.1111/ejh.13387

No abstract available

Keywords: CLL; Ibruitinib; front-line therapy; meta-analysis.

Publication types

Letter
Meta-Analysis
Systematic Review

MeSH terms

Adenine / administration & dosage
Adenine / adverse effects
Adenine / analogs & derivatives*
Adenine / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Molecular Targeted Therapy
Piperidines / administration & dosage
Piperidines / adverse effects
Piperidines / therapeutic use*
Prognosis
Proportional Hazards Models
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Treatment Outcome

Substances

Piperidines
Protein Kinase Inhibitors
ibrutinib
Adenine